Glycans and Cancer: How Sugar Patterns on Cells Reveal Disease Risk

Glycans and cancer research is shifting away from a narrow question, whether one glycoprotein can flag one tumour type, and toward a broader one: can the body's overall glycan pattern reveal systemic biological stress long before any disease is diagnosed? This matters because a whole systemic signal can be monitored over time, used to track the effect of an intervention, and support earlier, whole-body assessment rather than a single diagnostic snapshot. Research has repeatedly shown the importance of the plasma N-glycome, particularly how N-glycosylation of plasma glycoproteins relates to cancer-related processes generally, not a handful of named cancer types in isolation.

For a closer look at what these sugar structures are and how they connect to both biological age and immune health, see our full guide, Glycans: The Sugars That Reveal Your Biological Age and Immune Health.

Systemic glycan signatures, not single-organ snapshots

The same underlying mechanism, aberrant glycosylation on serum glycoproteins, shows up across very different parts of the body, which is why researchers increasingly treat glycans as a systemic signature rather than a series of organ-specific tests. Because most serum glycoproteins originate in the liver, liver disease is reflected in aberrant fucosylation of proteins such as alpha-fetoprotein (AFP): the glycosylated AFP-L3 fraction shows a significant increase in fucosylation among hepatocellular carcinoma patients compared with those with chronic liver disease, and the FDA has approved its use for early detection of this cancer. A similar pattern appears in the pancreas through increased fucosylation of haptoglobin, found significantly more often in pancreatic cancer patients than in those with other cancers or healthy controls. Both point to the same principle: fucosylation and related glycan modifications are a recurring signal of oncogenic activity, regardless of the organ involved. Existing single-protein markers show the limits of that approach alone; cancer antigen (CA) 19-9, for example, has a high false-positive rate and cannot reliably distinguish chronic pancreatitis from pancreatic cancer, which is why research is shifting towards broader glycan patterns rather than any one protein in isolation.

Why glycan changes appear before diagnosis

One of the more compelling findings in this field is how early these glycan changes can appear, often well before a disease becomes clinically detectable. Work on colorectal cancer has traced abnormal glycosylation patterns back to the premalignant stage, at the level of dysplasia, long before a diagnosis would typically be made.

"We found the gradual over-expression of this branching structure, catalysed by the GnT5 glycosyltransferase, along the colon carcinogenesis process. The highest levels of abnormal expression were observed as early as in premalignancy, at the level of dysplasia."
— Prof. Salomé Pinho, GlycanTrigger Coordinator, i3S, University of Porto

This pattern is not unique to cancer. Longitudinal research on insulin resistance has shown measurable N-glycome changes up to ten years before a formal diagnosis of type 2 diabetes, continuing steadily as diagnosis approaches, and similarly early changes in IgG galactosylation have been documented ahead of a rheumatoid arthritis diagnosis. Together, this supports a broader idea: the N-glycome is not a static, one-off diagnostic reading, but a dynamic reflection of the body's current inflammatory and immune state, often called inflammaging, which can shift years before any one disease is formally identified.

Can lifestyle change these glycan patterns?

If glycan patterns are dynamic rather than fixed, the natural question is whether they can be influenced. Diet research offers one answer: calorie reduction and weight loss shift the IgG glycome towards a less inflammatory profile, an effect driven more by calorie intake and weight change than by diet type. Regular moderate exercise has also been linked to a lower Glycan Age index and reduced inflammatory potential in IgG. Sleep and stress matter too: glycan structures linked to stress physiology shift with chronic psychological stress, including in combat-related post-traumatic stress disorder.

"Stress affects your glycans, and so does sleep. Everything that is known to be important for health actually affects IgG glycosylation. What you can do with glycans is make a lifestyle intervention, then after a couple of months check whether it worked."
— Prof. Gordan Lauc, Professor of Biochemistry and Molecular Biology, University of Zagreb, and Co-Founder & Chief Scientific Officer, GlycanAge

This is also why glycan testing is better understood as a monitoring tool than a one-off result. It captures the cumulative effect of diet, sleep, stress, exercise and hormonal status on the immune system, and it can be repeated to see whether a specific change is actually moving the needle.

What this means for monitoring immune-driven ageing

Across cancer and chronic disease research alike, the glycan signal is broader than any single tumour marker: it reflects the general inflammatory and immune tone of the body. Within GlycanAge's own index framework, lower levels of the anti-inflammatory Glycan Youth index have also been observed in groups that include cancer patients, older individuals and those with a higher BMI, consistent with research linking reduced protective glycosylation to inflammatory and oncogenic environments.

The IgG glycome, measured from a finger-prick blood sample, reveals this balance between anti-inflammatory and pro-inflammatory glycan structures in the immune system. GlycanAge tracks this systemic signal as a measure of biological age, showing how quickly or slowly someone is ageing relative to their chronological age. It measures and tracks general inflammatory tone rather than diagnosing, predicting or screening for any specific disease, including cancer; the value for a preventative, longevity-focused approach lies in tracking the trend over time, not in reading any single result as a diagnosis.

For practitioners already using AFP, CA19-9 or similar tumour markers diagnostically, an IgG glycosylation test serves a different purpose: a preventative, whole-body baseline that can be repeated to see whether an intervention, pharmaceutical, hormonal or lifestyle-based, is actually working. With a simple finger-prick sample and results typically ready in two to three weeks, retesting fits easily into an ongoing monitoring routine: generally every three to four months for a pharmaceutical or hormone-based intervention, or every six to twelve months for lifestyle-based changes.

Readers who want the broader science can start with our guide on what glycans are, or our overview of IgG glycosylation as the best marker of inflammaging. Practitioners exploring how immune-driven ageing markers fit into a wider assessment panel can find more detail in our guide to biological age testing for functional medicine practices.

Longevity-focused readers who want to see where their own immune-driven biological age currently stands can order a GlycanAge test kit directly, while those who want the full picture first can start with the complete guide on biological age testing.

External sources

• Adamczyk B, Tharmalingam T, Rudd PM. Glycans as cancer biomarkers. Biochim Biophys Acta. 2012;1820(9):1347-1353. PMID: https://pubmed.ncbi.nlm.nih.gov/22178561/

• Apweiler R, Hermjakob H, Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta. 1999;1473(1):4-8. PMID: https://pubmed.ncbi.nlm.nih.gov/10580125/

• Cvetko A, Mangino M, Tijardović M, Kifer D, Falchi M, Keser T, et al. Plasma N-glycome shows continuous deterioration as the diagnosis of insulin resistance approaches. BMJ Open Diabetes Res Care. 2021;9(1):e002263. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438737/

• Gudelj I, Salo PP, Trbojević-Akmačić I, Albers M, Primorac D, Perola M, et al. Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis. Biochim Biophys Acta Mol Basis Dis. 2018;1864(6 Pt A):2034-2039. PMID: https://pubmed.ncbi.nlm.nih.gov/29572115/

• Šimunić-Briški N, Dukarić V, Očić M, Madžar T, Vinicki M, Frkatović-Hodžić A, et al. Regular moderate physical exercise decreases Glycan Age index of biological age and reduces inflammatory potential of Immunoglobulin G. Glycoconj J. 2024;41(1):67-76. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10957704/

• Tudor L, Nedic Erjavec G, Nikolac Perkovic M, Konjevod M, Svob Strac D, Uzun S, et al. N-glycomic profile in combat related post-traumatic stress disorder. Biomolecules. 2019;9(12):834. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995522/

• Deriš H, Tominac P, Vučković F, Briški N, Gudelj I. Effects of low-calorie and different weight-maintenance diets on IgG glycome composition. Front Immunol. 2022;13:995186. PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535357/